NRx Pharmaceuticals (NRXP) Stock Price, News & Analysis

Company Overview

NRx Pharmaceuticals, Inc. is a clinical-stage specialty biopharmaceutical company focused on the development and repurposing of small-molecule therapeutics for central nervous system and rare disease indications. The company’s research strategy centers on advancing compounds with established safety profiles into new neurological and inflammatory conditions, leveraging translational science and biomarker-driven trial design to accelerate clinical development. NRx’s pipeline includes Ifenprodil, an NMDA receptor antagonist in investigation for acute respiratory distress syndrome and inflammatory muscle disorders, as well as investigational formulations targeting depressive and cognitive disorders.

Since securing global rights to its lead assets, NRx has initiated multiple proof-of-concept studies in the United States and Europe, collaborating with academic institutions and clinical research organizations to evaluate safety and efficacy across a range of indications. The company’s development programs are designed to address high-unmet-need patient populations, applying precision-medicine principles to optimize dosing regimens and patient selection. By building on decades of prior clinical experience with these molecules, NRx aims to reduce development timelines and costs relative to novel drug discovery.

Headquartered in New York, NRx Pharmaceuticals operates a lean corporate structure, with R&D activities supported by a network of external partners and contract research organizations. The company is led by a management team with deep expertise in pharmaceutical development, regulatory affairs and commercial strategy, drawing on experience at major biotech and global healthcare companies. Through strategic collaborations and disciplined capital allocation, NRx seeks to advance its product candidates efficiently toward regulatory milestones and, ultimately, market approval.

Key Stats

• Today's Range: $3.03 to $3.21
• 50-Day Range: $1.70 to $3.20
• 52-Week Range: $1.62 to $3.84
• Volume: 1.33 million shs
• Average Volume: 1.12 million shs
• Market Capitalization: $100.53 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $38.25
• Consensus Rating: Moderate Buy

NRx Pharmaceuticals Stock Analysis - MarketRank™

NRx Pharmaceuticals scored higher than 73% of companies evaluated by MarketBeat, and ranked 180th out of 856 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 4.3 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

NRx Pharmaceuticals has received a consensus rating of Moderate Buy. The company's average rating score is 2.50, and is based on no strong buy ratings, 4 buy ratings, 1 hold rating, and 1 sell rating.

Upside Potential

NRx Pharmaceuticals has a consensus price target of $38.25, representing about 1,158.2% upside from its current price of $3.04.

Amount of Analyst Coverage

NRx Pharmaceuticals has been the subject of 5 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

Earnings and Valuation

• Score: 1.9 / 5
• Proj. Earnings Growth: 846.15%

Earnings Growth

Earnings for NRx Pharmaceuticals are expected to grow by 846.15% in the coming year, from $0.13 to $1.23 per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of NRx Pharmaceuticals is -2.19, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of NRx Pharmaceuticals is -2.19, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Short Interest

• Score: 1.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

10.50% of the float of NRx Pharmaceuticals has been sold short.

Short Interest Ratio / Days to Cover

NRx Pharmaceuticals has a short interest ratio ("days to cover") of 4.62.

Change versus previous month

Short interest in NRx Pharmaceuticals has recently increased by 29.38%, indicating that investor sentiment is decreasing significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

NRx Pharmaceuticals does not currently pay a dividend.

Dividend Growth

NRx Pharmaceuticals does not have a long track record of dividend growth.

News and Social Media

• Score: 4.1 / 5
• News Sentiment: 1.54

News Sentiment

NRx Pharmaceuticals has a news sentiment score of 1.54. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.59 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 4 news articles for NRx Pharmaceuticals this week, compared to 5 articles on an average week.

Search Interest

15 people have searched for NRXP on MarketBeat in the last 30 days. This is an increase of 7% compared to the previous 30 days.

MarketBeat Follows

9 people have added NRx Pharmaceuticals to their MarketBeat watchlist in the last 30 days. This is an increase of 125% compared to the previous 30 days.

Company Ownership

• Score: 0.3 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, NRx Pharmaceuticals insiders have not sold or bought any company stock.

Percentage Held by Insiders

6.40% of the stock of NRx Pharmaceuticals is held by insiders.

Percentage Held by Institutions

4.27% of the stock of NRx Pharmaceuticals is held by institutions.

NRXP Stock Analysis - Frequently Asked Questions

How have NRXP shares performed this year?

NRx Pharmaceuticals' stock was trading at $2.71 at the start of the year. Since then, NRXP shares have increased by 12.2% and is now trading at $3.04.

How were NRx Pharmaceuticals' earnings last quarter?

NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) released its earnings results on Monday, March, 23rd. The company reported $0.19 EPS for the quarter, beating the consensus estimate of ($0.09) by $0.28. The business earned $0.98 million during the quarter, compared to analysts' expectations of $7.53 million.
Read the conference call transcript.

When did NRx Pharmaceuticals' stock split?

Shares of NRx Pharmaceuticals reverse split before market open on Tuesday, April 2nd 2024.The 1-10 reverse split was announced on Tuesday, April 2nd 2024. The number of shares owned by shareholders was adjusted after the closing bell on Tuesday, April 2nd 2024. An investor that had 100 shares of stock prior to the reverse split would have 10 shares after the split.

Who are NRx Pharmaceuticals' major shareholders?

Top institutional investors of NRx Pharmaceuticals include AdvisorShares Investments LLC (1.27%) and Ethos Financial Group LLC (0.05%). Insiders that own company stock include Jonathan C Javitt and Aaron Gorovitz.
View institutional ownership trends.

How do I buy shares of NRx Pharmaceuticals?

Shares of NRXP stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of NRx Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some other companies that NRx Pharmaceuticals investors own include NVIDIA (NVDA), Broadcom (AVGO), Arista Networks (ANET), Adobe (ADBE), Meta Platforms (META), GE Aerospace (GE) and Disc Medicine (IRON).

Company Calendar

• Last Earnings: 3/23/2026
• Today: 5/05/2026
• Next Earnings (Estimated): 5/21/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED - DRUGS
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:NRXP
• CIK: 1719406
• Web: www.bigrockpartners.com
• Phone: (484) 254-6134
• Fax: N/A
• Employees: 2
• Year Founded: 2015

Price Target and Rating

• Average Price Target for NRx Pharmaceuticals: $38.25
• High Price Target: $49.00
• Low Price Target: $25.00
• Potential Upside/Downside: +1,158.2%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.50
• Research Coverage: 6 Analysts

Profitability

• EPS (Trailing Twelve Months): ($1.39)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: 23.38
• P/E Growth: N/A
• Net Income: -$28.62 million
• Net Margins: N/A
• Pretax Margin: -2,336.49%
• Return on Equity: N/A
• Return on Assets: -265.03%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 0.31
• Quick Ratio: 0.31

Sales & Book Value

• Annual Sales: $1.23 million
• Price / Sales: 81.73
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: ($0.54) per share
• Price / Book: -5.63

Miscellaneous

• Outstanding Shares: 33,070,000
• Free Float: 30,952,000
• Market Cap: $100.53 million
• Optionable: Optionable
• Beta: 2.02